Events this week include Light in Winter Festival activities, new exhibits at the Johnson Museum of Art, inspirational talks at Sage Chapel, and a lecture on archaeology and photography. (Jan. 14, 2010)
More than 30 Human Ecology students, staff and faculty have signed on to become Green Ambassadors who will lead a peer-to-peer campaign to conserve campus resources and promote a culture of sustainability across the college.
Holding candles flickering in the twilight of March 8, hundreds of students gathered on Ho Plaza to honor Cornell's 13th president, Elizabeth Garrett, who died of colon cancer March 6.
Alice Pell, Cornell professor of animal science in the College of Agriculture and Life Sciences, took over as vice provost for international relations July 1. Here Pell discusses some of the duties of her office. (Nov. 7, 2008)
Artificial tissues with an embedded vascular system and a skull base sealer were two Cornell student inventions honored as finalists in the 2009 Collegiate Inventors Competition in Chicago, Oct. 18-20. (Oct. 21, 2009)
The Council for Advancement and Support of Education annual Circle of Excellence Awards has given bronze medals to two Cornell websites and a silver medal for alumni relations programs. (June 21, 2011)
New York, NY (May 20, 2002) Investigators from Weill Medical College of Cornell University today reported encouraging interim results with a new potential therapy for non-Hodgkinâs lymphoma (NHL), which affects about 53,900 new patients each year in the United States. The presentation was made at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.Dr. John P. Leonard, the lead investigator of a trial involving a collaboration of scientists from Weill Cornell, Amgen (of Thousand Oaks, CA), and Immunomedics (of Morris Plains, NJ), reported data from 21 patients who have relapsed and refractory NHLpatients in whom the disease has progressed despite prior treatment. The study is the first trial of a combination of two monoclonal antibodies in lymphomaone of the antibodies a known agent (rituximab) and the other a new one (epratuzumab). Administered together, once weekly for four weeks, the combination has preliminarily shown enhanced efficacy over that which has been previously reported with rituximab alone. Rituximab acts against the CD20 antigen (or target molecule) on NHL cells. Its brand name is Rituxan¨, and it is produced by IDEC, of San Diego, Calif., and Genentech, of San Francisco. Epratuzumab, a new investigational antibody in development by Amgen and Immunomedics, acts against the CD22 antigen of NHL.
For Cornell's second annual Fuel Cell Ride and Drive, representatives from Toyota, GM and Mercedes-Benz publicly displayed each company's hydrogen fuel-cell car prototype. (Oct. 20, 2009)
A new study surveyed Cornell's academic staff on the world's leading crises. No. 1 problem? Climate change. A more easily solved crisis? Insufficient education in science and critical thinking. (July 10, 2008)